Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

[1]  D. Kerr,et al.  Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial , 2003, The Lancet.

[2]  H. Rockette,et al.  Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Kerr,et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Zaniboni,et al.  Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  I. Seymour,et al.  ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[8]  H. Rockette,et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[10]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[11]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[12]  D. Cunningham,et al.  Mature results from three large controlled studies with raltitrexed ('Tomudex'). , 1998, British Journal of Cancer.

[13]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Cox.  Regression Models and Life-Tables , 1972 .